ArticleClinical, cosmetic and investigational dermatology2025
Evaluation of Pan-Immune-Inflammation Value (PIV) as a Predictive Biomarker for Psoriatic Arthritis in Patients with Psoriasis.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lower CALLY index values are associated with higher disease activity in psoriatic arthritis: a retrospective cohort study.Rheumatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Psoriasis (PsO) is a chronic inflammatory dermatosis that affects a significant portion of the global population and is associated with various comorbidities, including psoriatic arthritis (PsA). PsA develops in 20-30% of psoriasis patients and significantly impacts patient quality of life. Currently, early detection of PsA remains challenging, with no reliable, non-invasive biomarker for risk assessment. This study aims to evaluate the utility of pan-immune-inflammation value (PIV), along with other inflammatory indices, in predicting the development of PsA in patients with PsO. Methods: A retrospective analysis was conducted on 101 psoriasis patients (51 PsO, 50 PsA). Hematological parameters, including neutrophil, lymphocyte, monocyte, and platelet counts, were collected, and various inflammatory indices (PIV, SIRI, SII, NLR) were calculated. The diagnostic performance of these indices was assessed using Receiver Operating Characteristic (ROC) curve analysis. As a retrospective, double-center study with a limited sample size, the findings should be interpreted with caution and validated in larger, prospective cohorts. Results: The study found significant differences between PsA and PsO patients in terms of inflammatory indices, with higher PIV, SII, SIRI, and NLR levels observed in PsA patients. The diagnostic performance of PIV (AUC 0.63), SII (AUC 0.70), SIRI (AUC 0.64), and NLR (AUC 0.71) indicated that elevated levels of these indices could serve as potential markers for PsA risk. Additionally, PIV was significantly correlated with SII, SIRI, and NLR levels. Conclusion: PIV and other inflammatory indices, particularly NLR and SII, show promise as biomarkers for predicting the onset of PsA in patients with PsO. These findings may aid in early identification and timely intervention for PsA, improving patient outcomes and informing treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.